Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of TQB2210 in Advanced Malignant Tumors
NCT06929195Phase 1Completed
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- May 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB2210 in cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 2 more. Started May 2025; status: completed.
02
Drugs
TQB2210
03
Conditions
cancer
Beyond the preview
Go deeper on NCT06929195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929195.